Nanobiotix announces that a first patient has been randomized in the United States in the global phase 3 NANORAY-312 trial, evaluating its radioenhancer NBTXR3 in the treatment of elderly patients with head and neck cancer.

Radiation-activated NBTXR3 will be evaluated alone or in combination with cetuxima, in elderly patients with locally advanced head and neck cancer who are not eligible for platinum-based chemotherapy.

With the addition of the USA to Europe and Asia, patients are now being randomized in all major regions of the study. Futility analysis is scheduled for the second half of 2023, and interim data for the second half of 2024.

Copyright (c) 2022 CercleFinance.com. All rights reserved.